This is a multi-center randomized phase III clinical trial, the Inhibitor Prevention Trial,
in which Eloctate will be compared with Emicizumab, using adaptive design, to prevent
inhibitors in patients with severe hemophilia A.
Phase:
Phase 3
Details
Lead Sponsor:
Margaret Ragni
Collaborator:
Health Resources and Services Administration (HRSA)